Research guide / TB-500

What is TB-500? A Complete Research Guide.

Updated October 2026 · 8 minute read

TB-500 is a synthetic peptide based on the active region of thymosin beta-4, a naturally occurring protein involved in cell movement and tissue repair. This guide explains the difference between the two, what the research shows, and how much of it applies to humans.

Research information only. This article summarises published research. It is not medical advice, a dosing guide, or evidence that TB-500 is approved for any treatment. Most findings come from animal, laboratory, or full-length thymosin beta-4 studies.

01 / Overview

What is TB-500?

TB-500 is a synthetic peptide modelled on a short active region of thymosin beta-4 (Tβ4). A 2026 scoping review in Applied Sciences examined both molecules together because much of the TB-500 discussion borrows evidence from research on the full-length protein.[1]

Thymosin beta-4 itself is a 43-amino-acid protein and the most abundant member of the β-thymosin family, making up roughly 70–80% of β-thymosins in the body. It is found in high concentrations in platelets, white blood cells, and many tissues.[2]

The key distinction: TB-500 is not the same molecule as thymosin beta-4. Findings for one cannot automatically be transferred to the other, and almost no human research exists for TB-500 specifically.

View the BPC-157 + TB-500 research listing

02 / Mechanism

How is it thought to work?

Thymosin beta-4's best-understood role is binding actin, the protein that forms the cell's internal scaffolding. By regulating actin, Tβ4 influences how cells move — which matters for wound repair, where cells must migrate into damaged tissue. Reviews also describe roles in angiogenesis, reducing inflammation, and inhibiting cell death.[4]

A frequently cited 1999 rat study found that thymosin beta-4 applied topically or intraperitoneally increased reepithelialisation by 42% at day 4 and up to 61% at day 7 versus saline, with more collagen deposition and new blood vessels. It also stimulated keratinocyte migration in the laboratory.[5]

TB-500 is designed around the actin-binding region thought to drive these effects. Whether the fragment reproduces the full protein's activity in humans has not been established in controlled trials.

03 / Published evidence

What does the evidence actually show?

The 2026 scoping review mapped tissue-healing, regeneration, and musculoskeletal studies for both Tβ4 and TB-500. Its framing reflects the field: a substantial preclinical base, heavier on the full-length protein than on the synthetic fragment.[2]

Full-length thymosin beta-4 has been tested in human clinical trials for indications such as eye injuries, dermal wounds, and heart repair after myocardial infarction, according to reviews in Frontiers in Endocrinology and Expert Opinion on Biological Therapy. Note that the latter appeared in an industry-sponsored supplement.[3]

A 2019 European Journal of Dermatology review discussed Tβ4's potential in epidermolysis bullosa and severe dermal injuries. None of these clinical programmes used TB-500, and none has resulted in a widely approved thymosin beta-4 medicine.[4]

Shop BPC-157 + TB-500 pen

04 / Safety evidence

Safety and open questions

Because TB-500 itself has essentially no published human trial record, there is no established human safety profile. Safety information from full-length Tβ4 trials does not automatically apply to the fragment.[4]

Like BPC-157, TB-500 is associated with angiogenesis and cell migration — properties that are useful in wound repair and are also studied carefully in other biological contexts. No evidence links TB-500 to specific harms in humans; the data simply does not exist.[3]

TB-500 is prohibited by the World Anti-Doping Agency. It has been the subject of doping cases in human and equine sport, which reflects real-world use rather than evidence of benefit.

05 / Regulators

Regulatory status

TB-500 is not an approved medicine in the United States, the European Union, or other major jurisdictions. It circulates as a research compound and is banned in competitive sport.[3]

In the UAE, the Emirates Drug Establishment maintains the public registered medical product directory. This guide does not use directory presence or absence to infer approval, legality, or permission for use; those questions require confirmation from the EDE. Afiya Labs lists TB-500 strictly as a laboratory research reference material.[6]

06 / Quick answers

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-amino-acid natural protein. TB-500 is a synthetic peptide based on a short active region of it. Research on one does not automatically apply to the other.

Is TB-500 an approved medicine?

No. It is not approved by the FDA, EMA, or other major regulators, and it is prohibited in sport.

Why is TB-500 often paired with BPC-157?

Both are studied in soft-tissue repair research but through different proposed mechanisms — TB-500 via actin regulation and cell migration, BPC-157 via angiogenesis pathways. Researchers examine them side by side for that reason. Combination effects have not been established in human trials.

Has thymosin beta-4 been tested in humans?

Yes, the full-length protein has been studied in clinical trials for eye, skin, and heart indications. TB-500 specifically has not been through comparable trials.

Does Afiya Labs sell TB-500 for human use?

No. Afiya Labs lists TB-500 as a laboratory research reference material only. It is not a medicine and is not presented as suitable for human use.

07 / Sources